In a recent study, the Norwegian pharmaceutical company Bergenbio demonstrated that a Norwegian cancer drug could be effective against serious coronavirus.
The study shows that the drug has the potential to increase the proportion of those who survive without the need for respirator treatment by more than 50% of COVID-19 patients who are hospitalized, Bergenbio wrote in a press release.
The study looked at the drug bemcentinib, which was actually developed for cancer treatment but used on corona patients because the drug has a property that can build the cell’s resistance and thus be effective against several diseases.
“In a subgroup with increased severity (of the disease), survival without the use of a respirator was observed in 90% of patients treated with bemcentinib, compared to 72% of patients receiving standard treatment. Survival was numerically higher in patients treated with bemcentinib,” they stated.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at firstname.lastname@example.org